Despite the answers we are still seeking, huge progress has been made since the initial discovery of anti-cancer drugs – and all in a relatively short space of time. Indeed, the pace of advancement has never been more rapid than it is today. This paper traces the evolution of cancer treatment and drills down into the latest developments currently redefining the landscape, together with those on the horizon. All arguments and conclusions are supported by original quantitative research among treating oncologists in the EU and US.
Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.